Topic: Steve Brozak
Posted on 08/18/11 at 3:14pm by Abe Raymond . As biomedical research advances daily, medical devices are able to alleviate medical problems in...
Senomyx Inc. (SNMX) Q3 2010 Earnings Call November 04, 2010 11:00 am ET. Participating in this call from Senomyx will be Kent Snyder, Chief Executive Officer; John Poyhonen, President and Chief Operating Officer; Tony Rogers, Vice President and Chief Financial Officer ...
Geron Corporation (GERN) Q2 2010 Earnings Call Transcript July 30, 2010 11:00 am ET. Some of the patients who have non-squamous form of non-small cell lung will also be eligible for Avastin and those people will be stratified in the design ...
<div id="subtitle">Device, drugmaker J&amp;J needs revenue to rebound; investors also watching health reform impact</div><div><p>Johnson &amp; Johnson, the world's largest, most diverse health care company and a Dow Jones industrial average component, reports earnings ...
Sinovac Biotech Ltd. (SVA) Q4 2009 Earnings Call Transcript April 06, 2010 9:00 am ET. On the call today, we have Mr. Weidong Yin, CEO; Helen Yang, Investor Relations Manager; Vanessa Wu, Senior Financial Manager; and Chris Lee, Investor Relations. As ...
Biotech companies soar as federal government names new stem cell lines for testingShares of companies developing stem cell therapies surged Wednesday on news that the federal government has cleared 13 new stem cell lines for testing, bringing to a close nearly a ...
"Every CEO that I know in health care is in favor of this, but none that value their share prices will go on the record for fear of retribution from the FDA," said Steve Brozak, president of WBB Securities, an investment brokerage ...
Conceptus, Inc. (CPTS) Q4 2008 Earnings Call Transcript February 17, 2009 4:30 pm ET. Joining me this afternoon from Conceptus are Mark Sieczkarek, President and Chief Executive Officer and Greg Lichtwardt, Chief Financial Officer.. In our prepared remarks, Greg and I ...
Drugmaker Merck swings to 4Q profit, beats Wall Street forecasts despite lower salesDrugmaker Merck & A year ago, Whitehouse Station, N.J.-based Merck posted a loss of $1.63 billion, or 75 cents per share, mainly due to a $4.85 billion ...
Geron's human study on embryonic stem cell drug puts spotlight on sector's business prospectsGeron Corp. will enter uncharted territory when it begins the first federally approved human studies on an embryonic stem cell therapy, marking what some consider a major ...
